
Advertise on podcast: Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives
Rating
4.5from
This podcast has
223 episodes
Language
EnglishExplicit
No
Date created
2022/03/30
Latest episode
2026/11/16
Average duration
24 min.
Release period
7 days
Description
Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a podcast hosted by Drs. Diana Isaacs and Natalie Bellini aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care. A video version of each episode is available at HCPLive.com/Clinical/Endocrinology. Please direct podcast-related inquiries to [email protected]. Editor's note: Episodes predating January 2023 were hosted by Endocrinology Network. Episodes predating March 2022 were titled The Endocrine Outlook.
Unlock Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives podcast
OPTIMAL-DIABETES, Survodutide, and Orforglipron at AHA 2026
2026/11/16
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!Late-breaking data from the American Heart Association (AHA) Scientific Sessions 2026 are reopening debate on blood pressure targets in diabetes, the cardiovascular profile of dual incretin-glucagon agonists, and oral therapy for obstructive sleep apnea (OSA).
On a recent episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reviewed OPTIMAL-DIABETES, SYNCHRONIZE-CVOT, and ATTAIN-OSA and their implications for cardiometabolic care.
OPTIMAL-DIABETES randomized nearly 9500 adults aged 50 years and older with type 2 diabetes, elevated blood pressure, and high cardiovascular risk in Brazil to a systolic target below 120 mm Hg or below 140 mm Hg. Over roughly four years, intensive treatment lowered the relative risk of major cardiovascular events by 10%, a difference falling short of statistical significance. Achieved systolic pressures averaged about 122 mm Hg vs 135 mm Hg.
The neutral result contrasts with BPROAD, a Chinese trial in which stroke reduction drove benefit from a target of 120 mm Hg. A target of 130/80 mm Hg likely remains reasonable for most patients, with lower goals individualized against dizziness, falls, electrolyte disturbances, and frailty.
Survodutide, an investigational glucagon and glucagon-like peptide-1 (GLP-1) receptor dual agonist, met noninferiority for 5-point major adverse cardiovascular events in SYNCHRONIZE-CVOT. Among 5530 adults with a BMI of ≥27 kg/m² and cardiovascular disease or multiple risk factors, the primary endpoint occurred in 3.7% vs 4.1% with placebo (hazard ratio, 0.89). The CI crossed 1, and a median follow-up near 22 months limited any test of superiority.
Adverse events affected 93% of participants receiving 3.6 mg or 6 mg doses vs 85.6% with placebo. Gastrointestinal events leading to discontinuation separated the groups sharply, at 19.3% and 20.8% vs 1.9%, raising questions about titration.
In ATTAIN-OSA, once-daily oral orforglipron (Foundayo) reduced the apnea-hypopnea index at 52 weeks by 17.8 vs 4.5 events per hour without positive airway pressure (PAP) and by 17.3 vs 5.3 events per hour with PAP. Tirzepatide (Zepbound) already holds an OSA indication, but an oral option could reach patients averse to injections. Whether benefit extends beyond weight loss, and whether a small-molecule GLP-1 receptor agonist matches peptide cardiovascular outcomes, remains unresolved.
Collectively, the trials point toward individualized blood pressure goals in diabetes and a rising evidentiary bar for incretin-based therapies, where cardiovascular benefit, tolerability, and active-comparator data will increasingly shape agent selection.
Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.
Tubeless Mobi Clearance, CGM Choice, and Eversense Freedom
2026/11/16
In this episode of Diabetes Dialogue, co-hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, round up several recent developments across insulin pumps and continuous glucose monitoring. They discuss a new regulatory decision expanding wearable options for automated insulin delivery, including what it could mean for patient choice, site management, and day-to-day use. The hosts then turn to upcoming insurance coverage changes affecting glucose sensors and how practices are preparing patients ahead of the new year. They close with a look at early-stage work on the next generation of implantable sensors. Throughout, Isaacs and Bellini highlight how device design and payer decisions together shape which technologies actually reach patients.
Watch the full episode on HCPLive
Retatrutide Tops Semaglutide on A1C, Weight in T2D
2026/11/12
Triple agonism is reshaping expectations for weight loss in type 2 diabetes, a population historically less responsive to incretin-based therapy. New head-to-head phase 3 data show retatrutide more than doubled the weight reduction achieved with the highest approved dose of semaglutide (Ozempic).
On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reviewed topline results from the TRANSCEND-T2D-2 trial. Retatrutide is an investigational once-weekly agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors.
The open-label trial randomized 1298 adults with type 2 diabetes to retatrutide 9 mg, retatrutide 12 mg, or semaglutide 2 mg. From a mean baseline A1C of 8.3%, both retatrutide doses lowered A1C by 2.2 percentage points at 80 weeks vs 1.8 points with semaglutide. From a mean baseline weight of 102.4 kg, weight fell 19.5% with retatrutide 9 mg and 20.9% with 12 mg vs 9.4% with semaglutide.
With both agents producing substantial glycemic reductions, individual weight goals may increasingly guide agent selection. Patients needing A1C lowering without large weight loss, such as frail older adults at risk for falls and fractures, may be better suited to semaglutide.
Gastrointestinal events were common across all arms, with more diarrhea on retatrutide, slightly more constipation on semaglutide, and comparable rates of nausea. Discontinuation due to adverse events, however, reached 4.8% with retatrutide 9 mg and 7.9% with 12 mg vs 2.7% with semaglutide. Slower titration in practice, and use of the 9 mg dose, may help preserve tolerability without sacrificing much efficacy.
Cardiovascular outcomes remain the largest open question. Semaglutide and tirzepatide (Mounjaro) both carry cardiovascular indications, while the cardiovascular effects of adding glucagon receptor agonism to GIP and GLP-1 activity are unknown. For patients with type 2 diabetes and established cardiovascular disease, agents with proven outcome benefit remain the preferred choice.
Retatrutide is not FDA-approved, and compounded products of uncertain composition should be avoided. Full TRANSCEND-T2D-2 results are expected at a future medical meeting, and a placebo-controlled trial in roughly 320 adults inadequately managed with basal insulin should report in 2027.
Collectively, the findings position retatrutide as a potential option for patients with type 2 diabetes who need substantial weight reduction. Tolerability at higher doses and forthcoming cardiovascular data will likely determine its place alongside established incretin therapies.
Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.
CONNECT Trial Backs CGM in Non-Insulin Type 2 Diabetes
2026/11/12
Continuous glucose monitoring (CGM) is standard of care in insulin-treated diabetes, but evidence for its use in type 2 diabetes managed without insulin has lagged. New randomized data from the CONNECT trial suggest real-time CGM may substantially improve glycemic control in this much larger population.
On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, FNP-BC, spoke with Tom W. Martens, MD, of the International Diabetes Center, about CONNECT, recently published in the New England Journal of Medicine.
The trial enrolled 283 adults with type 2 diabetes who were not using insulin or CGM and had hemoglobin A1C levels of 7.5% or higher, across 22 primary care sites. Participants on stable non-insulin therapy were randomized 1:1 to real-time CGM with the Dexcom G7 or to routine fingerstick blood glucose monitoring (BGM) for 6.5 months. Both arms had the same number of brief, mostly virtual visits.
Mean A1C in the CGM group fell from 8.8% to 7.2%, a reduction of 1.6 percentage points. The BGM group improved from 8.7% to 8.0%, for a between-group difference of 0.9 percentage points. This gap is larger than those seen in earlier randomized CGM trials in insulin-treated type 2 diabetes, including MOBILE and DIAMOND.
Randomization was stratified by glucagon-like peptide-1 (GLP-1) receptor agonist use, reported by about 40% of participants at baseline. Among incretin users, A1C fell 1.4 percentage points with CGM vs 0.5 with BGM, the same 0.9-point difference. The benefit also held across other regimens, including sodium-glucose cotransporter 2 (SGLT2) inhibitors, used by about 30% of participants, and sulfonylureas.
More non-insulin therapies were added in the CGM arm. This may reflect access to continuous glucose data in place of infrequent A1C checks, which tend to reinforce clinical inertia. Much of the improvement appeared to come from lifestyle change, as participants could see postprandial excursions and link food choices to their glucose response.
The current American Diabetes Association (ADA) Standards of Care give CGM a grade C recommendation in non-insulin-treated type 2 diabetes. That grade reflects limited trial evidence, not proven lack of benefit. CONNECT may supply the randomized evidence needed for a grade A rating in the 2027 Standards, and payer coverage would likely follow over time.
A six-month extension, in which the BGM group switches to CGM, is still under way. Taken together, the findings suggest CGM adds to the effect of GLP-1 receptor agonists and other non-insulin therapies in primary care.
Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others. Martens reports disclosures with Dexcom, Abbott Diabetes, Sanofi, MannKind, Zealand Pharma A/S, Lilly, and others.
Building A Consensus Definition for Fully Closed-Loop Systems
2026/10/27
On this episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, talk with Brynn Marks, MD, MSHPEd, of Breakthrough T1D about where automated insulin delivery is headed. They discuss how next-generation systems might be evaluated and what the shift could mean for people with diabetes and the clinicians who support them.
Full episode: https://www.hcplive.com/view/diabetes-dialogue-a-consensus-definition-for-fully-closed-loop-systems
MiniMed Vivera Data and Twiist Type 2 Clearance
2026/10/23
Automated insulin delivery keeps moving toward systems that ask less of the people using them. In this episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, look at two recent developments and talk through what they mean for clinical practice.
In this episode:
First-in-human results for the MiniMed Vivera algorithm, and how it performed when participants skipped meal announcements
What the trial population can and can’t tell us about real-world patients
The FDA clearance of the twiist AID system for adults with insulin-treated type 2 diabetes
How the twiist algorithm differs from other systems, and tips for setting it up
Where reduced-burden AID could go next
Twiist AID Data and the New ADA/EASD Type 2 Algorithm
2026/10/16
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!Automated insulin delivery (AID) is becoming the standard approach for insulin-requiring type 2 diabetes (T2D), and new pivotal data suggest a fourth system may soon join the 3 already cleared for this population.On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reviewed 2 updates in T2D care. The discussion covered the Twiist AID trial and the new joint management algorithm from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD).The single-arm, multicenter trial, published in Diabetes Care, enrolled 307 adults aged 19 to 85 years with insulin-treated T2D who used the system for 13 weeks. Mean HbA1c fell 0.7%, from 8.1% to 7.4%, while continuous glucose monitoring time in range rose from 57% to 73%. Because every 5% gain in time in range carries clinical weight, a 16-point increase represents a substantial shift.Similar benefits appeared in adults older than 65 years, those using >100 units of insulin daily, and those taking glucagon-like peptide-1 (GLP-1) receptor agonists or sodium-glucose cotransporter 2 (SGLT2) inhibitors. Participants kept background therapy, and few counted carbohydrates at baseline. Fixed meal announcements, such as 45 g per meal with carbohydrate ratios adjusted behind them, and an extended-absorption bolus for gastroparesis or grazing patterns may simplify use.The ADA/EASD algorithm now integrates comorbidity assessment with glycemic and weight goals rather than splitting them into parallel pathways. Medical nutrition therapy, 24-hour physical activity behaviors, self-management education, and social determinants of health sit at the top. Directly below, the algorithm calls for early SGLT2 inhibitor and/or GLP-1-based therapy to modify disease and complication risk, a position metformin once held.A footnote extends the atherosclerotic cardiovascular disease recommendation to dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonists such as tirzepatide (Mounjaro), reflecting SURPASS-CVOT. Metabolic dysfunction-associated steatotic liver disease and steatohepatitis now sit beside chronic kidney disease and heart failure, with GLP-1-based therapy, low-dose pioglitazone, or SGLT2 inhibitors as options. An evidence graphic also links each additional 500 to 1,000 daily steps with lower all-cause and cardiovascular mortality.Collectively, the updates mark a move away from stepwise treat-to-fail escalation toward earlier organ-protective therapy and, once insulin is needed, automated delivery as the default.Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.
Screening, Cell Therapy, and Adjunctive Agents at Breakthrough-T1D
2026/10/15
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!
Population-level screening for type 1 diabetes (T1D) is moving into clinical practice, raising questions about who to screen, how to stage results, and how to deliver disease-modifying therapy at scale.
On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, recapped the inaugural Breakthrough T1D Clinical and Research Congress in Philadelphia.
First-degree relatives carry up to a 15-fold increased risk, and screening children at ages two, six, and 10 years identifies roughly 80% of those who will develop the disease. Evidence guiding adult screening and staging remains limited. One health system estimated up to 45,000 candidates after counting relatives and people with autoimmune thyroid disease, celiac disease, or vitiligo.
Placebo-controlled designs, such as the 14-day intravenous infusion regimen in the teplizumab (Tzield) TN10 trial, burden participants. An ongoing comparison of antithymocyte globulin with teplizumab gives every participant active therapy, and involving people with T1D in protocol development may improve enrollment. Eli Lilly is also investigating the Janus kinase inhibitor baricitinib (Olumiant) to delay progression from stage two to stage three disease.
Stem cell-derived islet programs from Vertex aim to overcome donor scarcity, with gene editing intended to reduce immunosuppression requirements. Reports of insulin independence with tegoprubart, an anti-CD40 ligand antibody from Eledon, involve few patients receiving infusions every three weeks, and long-term toxicity of agents such as tacrolimus remains a concern. Long-term Edmonton protocol data show many recipients sustain time in range above 90% despite resuming insulin.
Adjunctive agents layered on automated insulin delivery address residual cardiorenal risk. Dipeptidyl peptidase-4 inhibitors improve time in range without added hypoglycemia, while generic dapagliflozin lowers mean glucose but requires ketone monitoring given euglycemic diabetic ketoacidosis risk. Glucagon-like peptide-1 (GLP-1) and dual GIP/GLP-1 receptor agonists improve time in range, often at low doses such as tirzepatide (Mounjaro) 2.5 mg weekly.
Finerenone (Kerendia) recently gained approval for chronic kidney disease associated with T1D. The 2026 American Diabetes Association Standards of Care also recognize coexisting type 1 and type 2 diabetes, supporting coverage for patients with insulin resistance.
Supply policy compounds the clinical burden. Continuous glucose monitoring sensors frequently fail before their labeled wear time, leaving patients on standard monthly allotments without a sensor for meaningful stretches.
Collectively, these developments point toward individualized T1D care matched to disease stage and residual beta-cell function, with screening infrastructure, trial access, and supply policy shaping how quickly patients benefit.
Weekly Insulin Efsitora Alfa Gets FDA Approval for Type 2 Diabetes
2026/09/24
On this episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, FNP-BC, talk through the latest addition to the weekly basal insulin landscape and what it means for clinicians starting or switching patients. Their conversation centers on real-world considerations for bringing a new insulin option into practice.
Watch the video and get the full description: https://www.hcplive.com/view/diabetes-dialogue-weekly-insulin-efsitora-alfa-gets-fda-approval-for-type-2-diabetes
#Diabetes #Endocrinology #DiabetesDialogue
Finerenone Approved for CKD in Type 1 Diabetes
2026/09/18
Chronic kidney disease remains a persistent risk for people with type 1 diabetes, with roughly 30% of this population in the US developing the complication despite optimized glucose, blood pressure, and lipid management. Until now, no therapy directly targeted the mineralocorticoid receptor pathway implicated in this progression for this group.
On a recent episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discussed the US FDA approval of finerenone (Kerendia) for chronic kidney disease associated with type 1 diabetes.
The approval marks the first new therapy in 30 years for this population and represents the third indication for finerenone, following its approvals for chronic kidney disease with type 2 diabetes in 2025 and for heart failure with left ventricular ejection fraction above 40%. Regulators granted priority review, and the decision draws on a broader evidence base spanning roughly 20,000 patients across five pivotal phase 3 trials of the nonsteroidal mineralocorticoid receptor antagonist class.
The phase 3 FINE-ONE trial, a randomized, placebo-controlled, double-blind study, enrolled 242 adults with type 1 diabetes across nine countries and 80 sites and supported the approval. Finerenone added to standard of care reduced urine albumin-to-creatinine ratio (UACR) by 25% from baseline over six months compared with placebo. Overall, 68.1% of participants receiving finerenone achieved a UACR reduction of at least 30%, versus 46.6% with placebo, a threshold the American Diabetes Association associates with slowed CKD progression.
Finerenone carries a risk of hyperkalemia, requiring potassium monitoring, and should not be combined with steroidal mineralocorticoid receptor antagonists such as spironolactone or with concurrent ACE inhibitor and angiotensin receptor blocker therapy. Unlike SGLT2 inhibitors, which remain unapproved in type 1 diabetes due to concerns about euglycemic diabetic ketoacidosis, finerenone offers clinicians a mechanistically distinct option with a defined safety profile in this population.
The approval also renews attention on UACR screening, which remains underused in primary care despite annual screening recommendations for all patients with diabetes. Broader adoption of routine screening, paired with earlier mineralocorticoid receptor antagonist initiation, may extend the renoprotective gains demonstrated in FINE-ONE to more patients with type 1 diabetes.
Beta Bionics Mint Patch Pump Gains FDA Clearance
2026/09/15
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!Tubeless insulin delivery is entering a new phase of competition, as Beta Bionics announced FDA clearance of Mint, its first patch pump, alongside a forthcoming algorithm update designed to individualize glycemic targets without carb counting.1,2
On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discussed the clearance and its implications for practice. The conversation centered on device specifications, insurance pathways, and an upcoming three-mode dosing algorithm called 3D Intelligence.
Mint is a tubeless, three-day-wear pump holding 200 units of insulin, built around a nonrechargeable two-year battery and IPX8 water resistance rated to five feet for 60 minutes. It pairs with iOS and Android at launch and requires no phone for priming, addressing adherence barriers seen with existing automated insulin delivery systems. Sensor compatibility includes the Dexcom G7 and Abbott's Libre 3 Plus, with Libre Dual and Senseonics' Eversense integration planned to follow.
Beta Bionics expects to begin shipments in the first quarter of 2027, targeting production of approximately 1.5 million units for the year, with at least 40% of payers anticipated to offer pharmacy-benefit coverage at launch. This model would allow patients on any current pump, including those previously limited to durable medical equipment acquisition, to access Mint through pharmacy channels once coverage is in place.
The forthcoming 3D Intelligence update introduces three insulin-dosing profiles built on real-world data from more than 40,000 current iLet users, expanding on the meal-announcement-only interface which has defined the iLet since launch. The original mode preserves the existing algorithm, the optimized mode aims to reduce hypoglycemia while maintaining time above range, and the conservative mode delivers a more measured correction response for patients at higher hypoglycemia risk, such as older adults. The update remains pending FDA clearance but is expected to reach existing iLet users via software update around the Mint launch.
Expanded sensor compatibility, dual-platform smartphone support, and pharmacy-benefit access position Mint to broaden automated insulin delivery uptake beyond populations previously constrained to durable medical equipment coverage. Combined with the 3D Intelligence update, the changes reflect a shift toward individualized dosing within a system historically defined by simplicity, without reintroducing manual basal rates or carb-ratio calculations. As competing patch pump programs advance through the FDA pipeline, the addition reinforces momentum toward algorithm-driven, low-burden insulin delivery across the type 1 diabetes population.
Editors’ Note: Isaacs reports disclosures with Dexcom, Abbott, Lilly, Novo Nordisk, Medtronic, Insulet, and others. Bellini reports disclosures with Abbott Diabetes Care, MannKind, Povention Bio, and others.
Tirzepatide's New CV Indication and the STAREE Statin Trial
2026/09/10
In this episode of Diabetes Dialogue, co-hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, take on 2 recent developments that are reshaping how clinicians think about cardiovascular risk in people with diabetes. They start with a newly expanded indication for a dual incretin therapy, discussing what the supporting evidence means in practice and which patients may now be eligible. The hosts then turn to long-awaited trial evidence on statin therapy in older adults, a population historically underrepresented in this research. Along the way, they weigh open questions about mechanism, tolerability, and how to balance benefit against life expectancy and comorbidity. Throughout, Isaacs and Bellini emphasize individualized, shared decision-making when counseling patients on risk reduction at every age.
References
Eli Lilly and Company. FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes. Press release. August 28, 2026. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjaro-tirzepatide-reduce-cardiovascular
Zoungas S, Wolfe R, Moran C, et al. Atorvastatin, cardiovascular events, and disability-free survival in older adults. N Engl J Med. Published online August 28, 2026. doi:10.1056/NEJMoa2607314
Non-Invasive EEG Sensor Aims to Track Glucose in Real Time
2026/08/26
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!Non-invasive glucose monitoring is entering a new phase, with an EEG-based wearable positioned to sense blood sugar through brain rhythms rather than interstitial fluid. Early data from the developer suggest the approach may anticipate glucose changes ahead of standard continuous glucose monitors (CGMs), a claim rooted in the physiology of glucose transit from bloodstream to tissue.
On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Casey Halpern, MD, professor of neurosurgery and chief of stereotactic and functional neurosurgery at the University of Pennsylvania, about SynchNeuro, the company he cofounded to develop the device.
Halpern's group originally identified the underlying signal while using deep brain stimulation electrodes to study obesity and type 2 diabetes, finding that certain brain rhythms tracked blood glucose in real time regardless of electrode location. Because the signal is diffuse rather than localized, the team determined it could be captured non-invasively via scalp EEG, most reliably over the temporal lobe, an area accessible with a small sensor worn behind the ear. Device positioning has proven forgiving, with built-in signal-quality feedback guiding users to adjust placement as needed.
Accuracy data remain preliminary, drawn from EEG recordings paired with CGM readings in several dozen users over up to two weeks of continuous wear. Comparing readings synchronized to standard CGM timing, the sensor's mean absolute relative difference runs around 10% to 11%, approaching the accuracy range typically reported for interstitial fluid-based devices. Notably, Halpern reported that accuracy improves when comparing the sensor's output from 20 minutes earlier against subsequent CGM readings, suggesting the EEG signal reflects blood glucose upstream of the diffusion delay inherent to interstitial fluid sensing.
The company is enrolling additional users toward an algorithm-training cohort in the hundreds, which Halpern said internal power calculations suggest should be sufficient before pursuing regulatory clearance. Plans include an initial focus on type 2 diabetes and prediabetes, with a potential wellness-category launch preceding a full US Food and Drug Administration clinical-claims pathway. Beyond glucose, the platform is being explored for ketone monitoring, sleep apnea, and stroke risk prediction, applications that would each require separate regulatory work.
Collectively, the findings position EEG-based glucose sensing as a potential complement or alternative to interstitial fluid CGMs, particularly for patients seeking a non-invasive, intermittently wearable option, though larger validation cohorts and regulatory review will determine whether the anticipatory accuracy signal holds up at scale.
FreeStyle Libre Duo Cleared for Ketone Monitoring
2026/08/26
Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!Diabetic ketoacidosis remains a leading cause of preventable hospitalization in diabetes care, yet ketone testing has lagged far behind glucose monitoring in both accuracy and adoption. Continuous ketone monitoring aims to close this gap, giving clinicians and patients a real-time window into a metabolic state that urine strips and intermittent blood testing have rarely captured well.
On a recent episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, spoke with Eden Miller, DO, founder of Diabetes and Obesity Care, and Davida Kruger, NP, of Henry Ford Health, about the FDA clearance of the FreeStyle Libre Duo (Abbott), a combined glucose and ketone sensor. Both guests served on the international advisory board contributing to the sensor's development and co-authored related work in The Lancet.
The sensor pairs a 10-day wear with a 1-hour warm-up and reports glucose and beta-hydroxybutyrate readings every minute through the existing Libre app. Direct beta-hydroxybutyrate tracking offers an earlier signal than urine ketone testing, which measures acetoacetate and lags physiologic change. Ketone values 0.6 mmol/L default to a glucose-focused display, values between 0.6 and 3.0 mmol/L trigger a trend view with directional arrows, and a fixed threshold of 3.0 mmol/L generates an urgent high alert.
Guests emphasized glucose and ketone levels do not always move together. Pump-suspension research led by Jennifer Sherr, MD, PhD, at Yale, showed considerable variability in time to ketosis, with some patients developing ketosis within 4 hours of an interruption and others remaining ketone-free well beyond it. This variability carries particular relevance for patients using sodium-glucose cotransporter-2 (SGLT2) inhibitors off-label in type 1 diabetes, since euglycemic ketosis can develop without corresponding hyperglycemia.
At launch, the sensor is expected to pair with select automated insulin delivery systems, including Beta Bionics' iLet, with expanded compatibility anticipated for Omnipod 5 and Medtronic's Instinct sensor into 2027, though no pump algorithm will adjust dosing based on ketone data yet. Coverage will begin through commercial insurance only, without Medicare or Medicaid reimbursement established at this time. Clinicians will need updated protocols to interpret ketone trend arrows manually, distinguishing benign nutritional ketosis from evolving decompensation before automated support becomes available.
Continuous ketone monitoring marks a shift comparable to the early adoption of continuous glucose monitoring, when clinicians needed guidance interpreting new, high-frequency physiologic data. As real-world experience accumulates over the coming year, the technology is positioned to inform individualized ketone thresholds, refine detection of infusion-set failure, and potentially reduce emergency care tied to diabetic ketoacidosis.
Ultra-rapid insulin, IcoSema advance in type 2 diabetes
2026/08/24
Insulin-resistant patients with type 2 diabetes who require high-dose therapy have long lacked a rapid-acting option concentrated enough for compact insulin pumps. New pharmacokinetic data on an ultra-rapid U-500 insulin aspart, alongside additional phase 3 results for a combined once-weekly insulin icodec-semaglutide regimen, both aim to close persistent gaps in insulin delivery for this population. In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, reviewed two studies addressing unmet needs in insulin therapy for type 2 diabetes.
The investigational agent AT278 is a highly concentrated insulin aspart formulated at 500 units/mL, distinct from existing U-500 regular human insulin, which behaves more like an intermediate-acting product. In a single-center, randomized, double-blind, crossover euglycemic clamp study spanning body mass index from 25 to 38 kg/m², AT278 produced significantly faster absorption and a greater glucose-lowering effect within the first hour versus both standard U-100 insulin aspart and U-500 regular human insulin. The ultra-rapid pharmacokinetic and pharmacodynamic profile held consistent across the BMI range studied.
Current U-500 regular insulin requires dosing 30 minutes before meals while simultaneously serving as basal and prandial coverage, complicating use in automated insulin delivery systems and limiting compatibility with smaller-volume pumps. A concentrated, rapid-onset formulation could allow patients with high insulin requirements to use compact pumps and extended-wear infusion sets without the absorption problems tied to large-volume subcutaneous depots. Drawn from an early-phase study, the findings position AT278 as a potential first ultra-rapid option for prandial dosing in this population, though regulatory approval for pump use remains undefined.
Separately, the phase 3 COMBINE 4 trial evaluated a fixed combination of once-weekly insulin icodec (Awiqli) and semaglutide, known as IcoSema, against once-daily insulin glargine U-100 in 485 adults with type 2 diabetes and baseline A1C above 8%. Over 40 weeks, IcoSema reduced A1C by 3.32 percentage points versus 2.44 points with glargine, a between-group difference of 0.88 percentage points, while producing a 0.79 kg weight reduction compared with a 3.81 kg gain with glargine. Time in range reached 79.8% with IcoSema versus 64.5% with glargine, consistent with the mechanistic rationale of pairing glucagon-like peptide-1 receptor agonism with basal insulin to limit postprandial excursions.
These results build on earlier COMBINE 1 through 3 data, which showed IcoSema achieving noninferior or superior A1C reduction, superior weight outcomes, and lower hypoglycemia rates versus comparators. A single weekly injection combining basal insulin with a GLP-1 receptor agonist could reduce treatment burden and consolidate pharmacy copays, though semaglutide exposure remains capped by concurrent insulin titration, averaging 0.66 mg in COMBINE 4. Whether either agent reaches United States practice, including reported uncertainty around a domestic IcoSema launch, will determine their eventual role in managing insulin-resistant type 2 diabetes.
Podcast reviews
Read Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives podcast reviews
WGallagher 2026/09/07
Excellent Podcasts
These podcasts are so educational. I always look forward to hearing both perspectives on new products and devices in development or new to market. Kee...
cmps25 2026/04/04
Congratulations
Really good with the latest updates.
Would like if Nathalie can be more concise when she talks
AEB9857 2024/01/24
Excellent podcast!
Highly recommend for people living with diabetes! Thanks so much for the technology updates and diabetes management info you provide! :)
Podcast sponsorship advertising
Start advertising on Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives relevant audience podcasts
You may also like to advertise on these Podcasts

4.6908522
You Can Heal Your Life ™
Hay House

4.41164993
Extratime
Major League Soccer

4.8815227
ArtCurious Podcast
Jennifer Dasal/ArtCurious

4.9328581397
REAL AF with Andy Frisella
Andy Frisella

3.99067574
20/20
ABC News

4.91366715
The Learning Leader Show With Ryan Hawk
Ryan Hawk

4.92110505
the bossbabe podcast
Natalie Ellis

4.3387182001
The Megyn Kelly Show
SiriusXM

4.947999419
The Shawn Ryan Show
Shawn Ryan

4.5185359
Who, When, Wow!
Tinkercast | Wondery